Oneness Biotech

4743.TWO

1.45 USD

-0.02

-1.36%

Overview

Last close

1.45 usd

Market cap

693.35M usd

52 week high

2.59 usd

52 week low

1.27 usd

Target price

9.51 usd

Valuation

P/E

360

Forward P/E

N/A

Price/Sales

145.9238

Price/Book Value

2.2528

Enterprise Value

555.83M usd

EV/Revenue

117.1061

EV/EBITDA

43.4032

Key financials

Revenue TTM

4.75M usd

Gross Profit TTM

1.75M usd

EBITDA TTM

-15.68M usd

Earnings per Share

-0.07 usd

Dividend

N/A usd

Total assets

354.36M usd

Net debt

N/A usd

About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.